New investigational drug for indolent systemic mastocytosis

Trial ID:
IRB-25-8532
Andrew A. White, M.D.

Inclusion Criteria

Patients must:

  • Have a diagnosis of indolent systemic mastocytosis (ISM) confirmed by bone marrow biopsy
  • Have moderate-to-severe symptoms while taking standard medications
  • Be over 18 years old

Exclusion Criteria

Patients must not:

  • Have had any prior treatment with bezuclastinib, elenestinib, or another targeted KIT inhibitor; patients treated with avapritinib may be eligible
  • Have had any prior treatment with BTK inhibitor, BMX inhibitor, or PI3K inhibitor
  • Require proton-pump inhibitors (omeprazole, pantoprazole, esomeprazole, lansoprazole, etc)

Additional Info

Study visits primarily take place at Scripps Clinic Carmel Valley with some study procedures occurring at Scripps Prebys Cancer Center.

For more information search NCT# 04655118 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org